EDITORIAL
Anti-acid therapy in Idiopathic Pulmonary Fibrosis: to treat or not to treat?
 
More details
Hide details
1
7th Department of Pneumonology, Athens Chest Hospital, Greece
2
2nd Pulmonary Medicine Department, Attikon University Hospital, Athens Medical School National and Kapodistrian University of Athens, Greece
3
1st Department of Pneumonology, Athens Chest Hospital, Athens Medical School, National and Kapodistrian University of Athens, Greece
CORRESPONDING AUTHOR
Demosthenes Bouros   

Athens Chest Diseases General Hospital ‘Sotiria’, 152 Mesogion Αv., Athens 11527, Greece
 
Pneumon 2016;29(3):196–199
 
KEYWORDS
CONFLICTS OF INTEREST
All the authors declare that they do not have a financial relationship with a commercial entity that has an interest in the subject of this manuscript.
 
REFERENCES (25)
1.
Raghu G, Collard HR, Egan JJ, et al. An official ATS/ERS/JRS/ ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management. Am J Respir Crit Care Med 2011;183:788-824.
 
2.
King TE Jr, Pardo A, Selman M. Idiopathic pulmonary fibrosis. Lancet 2011;378:1949-61.
 
3.
Mays EE, Dubois JJ, Hamilton GB. Pulmonary fibrosis associated with tracheobronchial aspiration. A study of the frequency of hiatal hernia and gastroesophageal reflux in interstitial pulmonary fibrosis of obscure etiology. Chest 1976;69:512-5.
 
4.
Raghu G, Amatto VC, Behr J, Stowasser S. Comorbidities in idiopathic pulmonary fi brosis patients: a systematic literature review. Eur Respir J 2015;46:1113-30.
 
5.
Lee JS, Ryu JH, Elicker BM, et al. Gastroesophageal reflux therapy is associated with longer survival in patients with idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2011;184:1390-4.
 
6.
Houghton LA, Lee AS, Badri H, DeVault KR, Smith JA. Respiratory disease and the oesophagus: reflux, reflexes and microaspiration. Nat Rev Gastroenterol Hepatol 2016;13:445-60.
 
7.
Tcherakian C, Cottin V, Brillet PY, et al. Progression of idiopathic pulmonary fibrosis: lessons from asymmetrical disease. Thorax 2011;66:226-31.
 
8.
Ghebre YT, Raghu G. Idiopathic Pulmonary Fibrosis: Novel Concepts of Proton Pump Inhibitors as Antifibrotic Drugs. Am J Respir Crit Care Med 2016;193:1345-52.
 
9.
Noth I, Zangan SM, Soares RV, et al. Prevalence of hiatal hernia by blinded multidetector CT in patients with idiopathic pulmonary fibrosis. Eur Respir J 2012;39:344-51.
 
10.
Raghu G, Rochwerg B, Zhang Y, et al. An official ATS/ERS/JRS/ALAT clinical practice guideline: treatment of idiopathic pulmonary fibrosis. An update of the 2011 clinical practice guideline. Am J Respir Crit Care Med 2015;192: e3-e19.
 
11.
Lee JS, Collard HR, Anstrom KJ, et al; IPFnet Investigators. Antiacid treatment and disease progression in idiopathic pulmonary fibrosis: an analysis of data from three randomised controlled trials. Lancet Respir Med 2013;1:369-76.
 
12.
Kreuter M, Wuyts W, Renzoni E, et al. Anti-acid therapy and disease outcomes in idiopathic pulmonary fibrosis: a pooled analysis. Lancet Respir Med 2016;4:381-9.
 
13.
Raghu G, Crestani B, Bailes Z, et al. Effect of anti-acid medication on reduction in FVC decline with nintedanib. Eur Respir J 2015;46:Suppl. 59, OA4502.
 
14.
Raghu G, Bailes Z, et al. Effect of anti-acid medication on reduction in FVC decline with nintedanib. Eur Respir J 2015;46:Suppl. 59, OA4502.
 
15.
Raghu G. Anti-acid treatment in patients with IPF: interpret results from post-hoc, subgroup, and exploratory analyses with great caution. Lancet Respir Med 2016;4:e46-7.
 
16.
European Medicines Agency. Esbriet product information. www.ema.europa.eu/docs/en_GB/d.... Date last accessed: September 19, 2016.
 
17.
Raghu G, Meyer KC. Silent gastro-oesophageal reflux and microaspiration in IPF: mounting evidence for anti-reflux therapy? Eur Respir J 2012;39:242-5.
 
18.
Raghu G, Morrow E, Collins BF, et al. Laparoscopic anti-reflux surgery for idiopathic pulmonary fibrosis at a single centre. Eur Respir J 2016;48:826-32.
 
19.
Han MK, Zhou Y, Murray S, et al. COMET Investigators. Lung microbiome and disease progression in idiopathic pulmonary fibrosis: an analysis of the COMET study. Lancet Respir Med 2014;2:548-56.
 
20.
Molyneaux PL, Cox MJ, Willis-Owen SA, et al. The role of bacteria in the pathogenesis and progression of idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2014;190:906-13.
 
21.
Ghebremariam YT, Cooke JP, Gerhart W, et al. Pleiotropic effect of the proton pump inhibitor esomeprazole leading to suppression of lung inflammation and fibrosis. J Transl Med 2015;13:249.
 
22.
Tzouvelekis A, Bouros D. Anti-acid treatment for idiopathic pulmonary fibrosis. Lancet Respir Med 2013;1:348-9.
 
23.
Bouros D, Tzouvelekis A. Idiopathic pulmonary fibrosis: on the move. Lancet Respir Med 2014;2:17-9.
 
24.
http://www.clinicaltrials.gov/ Pilot Trial Of Omeprazole in Idiopathic Pulmonary Fibrosis (IPF) (PPIPF). https://clinicaltrials.gov/ct2.... Date last accessed: September 19, 2016. Clinical Trials identifier: NCT02085018.
 
25.
http://www.clinicaltrials.gov/ Treatment of IPF with laparoscopic anti-reflux surgery (WRAP-IPF). https://clinicaltrials.gov/ct2.... Date last accessed: September 19, 2016. Clinical Trials identifier: NCT01982968.
 
eISSN:1791-4914
ISSN:1105-848X